dc.contributor | Departament de Salut |
dc.contributor.author | Programa d'Harmonització Farmacoterapèutica |
dc.date.accessioned | 2021-09-10T09:00:10Z |
dc.date.available | 2021-09-10T09:00:10Z |
dc.date.issued | 2020-11-17 |
dc.identifier.citation | Programa d'Harmonització Farmacoterapèutica. Neratinib, pertuzumab o trastuzumab emtansina per al tractament adjuvant del càncer de mama precoç HER2+. Barcelona: Servei Català de la Salut; 2020. |
dc.identifier.uri | https://hdl.handle.net/11351/6291 |
dc.description | Neratinib; Pertuzumab; Trastuzumab emtansine; HER2 + early breast cancer |
dc.description.abstract | Breast cancer (CM) is the most common cancer in women worldwide. In Spain, 32,953 new cases were diagnosed in 2019 and it is estimated that there are about 6,000-6,500 deaths a year from this cause. Breast cancer is a biologically diverse disease, with different subgroups defined according to their genomic or molecular characteristics. In the clinical field, three groups with different therapeutic needs are usually defined: tumors with positive estrogen (RE) +/– progesterone (RPg) hormone (RPg) hormone receptors (hormone-dependent or luminal) and negative HER2 (RH + and HER2–). ; HER2-positive tumors (overexpress HER2 protein), and triple-negative (TN) tumors (with RH and HER2-negative). Approximately 65-70% of cases are RH + and HER2 negative tumors; 15-20%, HER2 +, and 15%, TN . |
dc.language.iso | cat |
dc.publisher | Servei Català de la Salut |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Evaluation |
dc.title | Neratinib, pertuzumab o trastuzumab emtansina per al tractament adjuvant del càncer de mama precoç HER2+ |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | evaluación de medicamentos |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |